Sectors
Tech
Healthcare
Consumer
Energy
Mining & Metals
Business Services
Financials
Telecom
Industrials
Transportation
Aerospace & Defense
Real Estate
Utilities
Spotlight Stocks
CEO Interview
Investor Presentations
Newsmakers
Investing Strategy
Investment Research – Sponsored Reports
Analyst Reports
Insider Trading
Smart Money
Funds & ETF’s
Markets
Commodities
Currencies
Economy
Lending & Interest Rates
Business News
Trading Ideas
Executive Resources
Leadership & Strategy
Capital
Law
Investor Education
Long Term Investing
Personal Finance
Stock Trading
Options Trading
Forex Trading
Futures Trading
EVENTS
Next Super Stock LIVE! – The Online Investor Conference
INVESTORS DISCOVERY DAY Livestream
Newswire
[ March 25, 2025 ]
Predictive Oncology (NASDAQ: POAI) Successfully Develops Predictive Models Derived from Never-Before-Seen Compounds for Prevalent Cancer Indications Including Breast, Colon and Ovary
Newsmakers
[ March 25, 2025 ]
Tenon Medical (NASDAQ:TNON) Announces FDA Clearance of Catamaran(R) SI Joint Fusion System for New Indication to Augment Spinal Fusion
Newsmakers
[ March 24, 2025 ]
Damon Inc. (NASDAQ: DMN) Announces Closing of Upsized $16.5 Million Underwritten Public Offering
Newsmakers
[ March 18, 2025 ]
ABVC BioPharma (NASDAQ: ABVC) CEO Interview with Uttam Patil
CEO Interview
[ March 17, 2025 ]
Hyperfine (NASDAQ: HYPR) and NVIDIA Collaborate to Revolutionize Neuroimaging with AI-Powered Innovation
Newsmakers
[ March 13, 2025 ]
FDA Issues Clearance for ReWalk 7 Exoskeleton (NASDAQ: LFWD)
Newsmakers
[ March 13, 2025 ]
ImmunoPrecise (NASDAQ: IPA)Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.
Newsmakers
[ March 13, 2025 ]
“Pure Play on US Drone Market” Unusual Machines (NYSE: UMAC) CEO Interview with Allan Evans
Aerospace & Defense
[ March 6, 2025 ]
Plus Therapeutics (NASDAQ: PSTV) Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
Newsmakers
[ March 3, 2025 ]
BioXcel Therapeutics (NASDAQ: BTAI) Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s Dementia
Newsmakers
Home
Publish Your News Release
Publish Your News Release
[wpuf_form id=”76965″]
Contact
About Us
Investor Relations Services
Terms of Use/Legal Notice
Login
Subscriptions
Submit Press Release
Privacy Policy
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.